Presentation is loading. Please wait.

Presentation is loading. Please wait.

Montalescot G, et al. Lancet 2009;373:723-31. Trial profile Montalescot G, et al. Lancet 2009;373:723-31.

Published byPrecious Ellenwood Modified over 9 years ago

Similar presentations

Presentation on theme: "Montalescot G, et al. Lancet 2009;373:723-31. Trial profile Montalescot G, et al. Lancet 2009;373:723-31."— Presentation transcript:

1 Montalescot G, et al. Lancet 2009;373:723-31

2 Trial profile Montalescot G, et al. Lancet 2009;373:723-31

3 Baseline characteristics of STEMI cohort, by drug allocation and type of PCI Montalescot G, et al. Lancet 2009;373:723-31

4 Major efficacy and safety endpoints at 30 days Montalescot G, et al. Lancet 2009;373:723-31

5 Major efficacy and safety endpoints at 15 months Montalescot G, et al. Lancet 2009;373:723-31

6 Kaplan-Meier curves for selected endpoints Montalescot G, et al. Lancet 2009;373:723-31

Download ppt "Montalescot G, et al. Lancet 2009;373:723-31. Trial profile Montalescot G, et al. Lancet 2009;373:723-31."

Similar presentations

Sibbing D, et al. J Am Coll Cardiol 2009;53:849-56.

Sibbing D, et al. J Am Coll Cardiol 2009;53:
Trial profile Fox K et al. Lancet 2008;372:807-16.

Trial profile Fox K et al. Lancet 2008;372:
Objective:To assess the effect of various clopidogrel and aspirin regimens on major CV events and ST in ACS patients undergoing PCI. Study:Multicenter,

Objective:To assess the effect of various clopidogrel and aspirin regimens on major CV events and ST in ACS patients undergoing PCI. Study:Multicenter,
Safety and Efficacy of Intravenous Enoxaparin in Elective Percutaneous Coronary Intervention: An International Randomised Evaluation One year follow-up.

Safety and Efficacy of Intravenous Enoxaparin in Elective Percutaneous Coronary Intervention: An International Randomised Evaluation One year follow-up.
Trial profile Prakash Deedwania, et al. Lancet 2006; 368: 919-28.

Trial profile Prakash Deedwania, et al. Lancet 2006; 368:
TRITON TIMI-38 STEMI cohort Primary End Point (CV death, MI and stroke at 15 months) Adapted from Montalescot et al. ESC 2008. Time (days) 5 10 15 0 050100150200250300350400.

TRITON TIMI-38 STEMI cohort Primary End Point (CV death, MI and stroke at 15 months) Adapted from Montalescot et al. ESC Time (days)
Trial profile Mann JF et al. Lancet 2008;372:547-53.

Trial profile Mann JF et al. Lancet 2008;372:
TRITON TIMI-38 STEMI cohort Clopidogrel Under Fire: Is Prasugrel in Primary PCI or Recent MI Superior? Insights From TRITON-TIMI-38 Gilles Montalescot,

TRITON TIMI-38 STEMI cohort Clopidogrel Under Fire: Is Prasugrel in Primary PCI or Recent MI Superior? Insights From TRITON-TIMI-38 Gilles Montalescot,
Mega JL, et al. N Engl J Med 2009;360:354-62. Genetic Effects on Pharmacokinetic and Pharmacodynamic Responses to Clopidogrel Mega JL, et al. N Engl J.

Mega JL, et al. N Engl J Med 2009;360: Genetic Effects on Pharmacokinetic and Pharmacodynamic Responses to Clopidogrel Mega JL, et al. N Engl J.
Volume 386, Issue 9988, Pages (July 2015)

Volume 386, Issue 9988, Pages (July 2015)
Volume 385, Issue 9985, Pages (June 2015)

Volume 385, Issue 9985, Pages (June 2015)
Dolutegravir versus Raltegravir in Treatment Experienced SAILING Study

Dolutegravir versus Raltegravir in Treatment Experienced SAILING Study
Impella 2.5® Device Is Associated with Improved Survival in AMICS

Impella 2.5® Device Is Associated with Improved Survival in AMICS
EARLY-BAMI Trial design: Patients presenting with STEMI with a plan for primary PCI, and without evidence of cardiogenic shock, were randomized to either.

EARLY-BAMI Trial design: Patients presenting with STEMI with a plan for primary PCI, and without evidence of cardiogenic shock, were randomized to either.
 Kaplan-Meier survival curves by frequency of exacerbations in patients with COPD: group A, patients with no acute exacerbations of COPD; group B, patients.

 Kaplan-Meier survival curves by frequency of exacerbations in patients with COPD: group A, patients with no acute exacerbations of COPD; group B, patients.
PAD Patients vs Post-ACS Patients:

PAD Patients vs Post-ACS Patients:
Patient disposition for the double-blind study period.

Patient disposition for the double-blind study period.
The Safety and Efficacy of Full vs

The Safety and Efficacy of Full vs
ATLANTIC Trial design: Participants with STEMI being transported for primary PCI were randomized in the ambulance to ticagrelor 180 mg (n = 909) vs. placebo.

ATLANTIC Trial design: Participants with STEMI being transported for primary PCI were randomized in the ambulance to ticagrelor 180 mg (n = 909) vs. placebo.
Baseline characteristics of patients

Baseline characteristics of patients

Similar presentations

Ads by Google